Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM21menos65: Extended VRD + ERI vs Isatuximab-VRD vs Isatuximab-VID in NDMM
NCT05558319Phase 3Recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of isatuximab, iberdomide in multiple myeloma (MM), sponsored by Fundación PETHEMA. Started Nov 2022; status: recruiting.
02
Drugs
isatuximabiberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05558319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558319.